QURE: uniQure N.V.
Performance
QURE -17.99%
Watchlist
Select an item
Summary
QURE at a glance
QURE returned -17.99% over the past year and -8.32% a year over five years. Its worst drop in that year was -70.72%, smaller than 5% of stocks on Redstone, and its Sharpe ratio of 0.43 beats 47% of stocks on Redstone. It pays no dividends.
Current Drawdown
-55.36%
Rolling Volatility
75.54%
Actions
Metrics
Risk Indicators
Alpha52.05%
Beta0.57x
Sharpe0.43
Sortino0.76
Omega1.11
Calmar-0.25
Martin1.81
Profile
About QURE
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.6B
- Listed
- Feb 2014
- Employees
- 221
- Headquarters
- Amsterdam
- Website
- uniqure.com
Comparisons